Raymond James & Associates Mersana Therapeutics, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
Shares
1 transactions
Others Institutions Holding MRSN
# of Institutions
130Shares Held
104MCall Options Held
58.5KPut Options Held
471K-
Nextech Invest Ag12.1MShares$7 Million3.22% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.3MShares$6.57 Million0.76% of portfolio
-
Vr Adviser, LLC New York, NY10.3MShares$5.95 Million2.42% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$5.02 Million3.35% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$4.86 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $56.4M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...